Atlas Trials

A Phase 1/2 Study to Investigate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of HMB-001 in Glanzmann Thrombasthenia

Clinical trial NCT06211634 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT06211634
Sponsor
Hemab ApS
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Glanzmann Thrombasthenia
Start date
2022-12-13
Primary completion
2027-08-01
Enrollment
57

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.